The impact of proton pump inhibitors on the course of ulcerative colitis: a cohort study of over 10,000 newly diagnosed patients in Norway

References

• Lloyd-Price J, Arze C, Ananthakrishnan AN, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569(7758):655–662. doi: 10.1038/s41586-019-1237-9.
   PubMed Web of Science ®Google Scholar
• Caruso R, Lo BC, Núñez G. Host-microbiota interactions in inflammatory bowel disease. Nat Rev Immunol. 2020;20(7):411–426. doi: 10.1038/s41577-019-0268-7.
   PubMed Web of Science ®Google Scholar
• Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA. 2011;108 Suppl 1(Suppl 1):4554–4561. doi: 10.1073/pnas.1000087107.
   PubMedGoogle Scholar
• Nguyen LH, Örtqvist AK, Cao Y, et al. Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden. Lancet Gastroenterol Hepatol. 2020;5(11):986–995. doi: 10.1016/S2468-1253(20)30267-3.
   PubMed Web of Science ®Google Scholar
• Örtqvist AK, Lundholm C, Halfvarson J, et al. Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: a population-based study. Gut. 2019;68(2):218–225. doi: 10.1136/gutjnl-2017-314352.
   PubMed Web of Science ®Google Scholar
• Sharma BK, Santana IA, Wood EC, et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with ­omeprazole. Br Med J (Clin Res Ed). 1984;289(6447):717–719. doi: 10.1136/bmj.289.6447.717.
   PubMedGoogle Scholar
• Clooney AG, Bernstein CN, Leslie WD, et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(9):974–984. doi: 10.1111/apt.13568.
   PubMed Web of Science ®Google Scholar
• Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–748. doi: 10.1136/gutjnl-2015-310376.
   PubMed Web of Science ®Google Scholar
• Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352(6285):565–569. doi: 10.1126/science.aad3369.
   PubMed Web of Science ®Google Scholar
• Schwartz NRM, Hutfless S, Herrinton LJ, et al. Proton pump inhibitors, H(2) blocker use, and risk of inflammatory bowel disease in children. J Pediatr Pharmacol Ther. 2019;24(6):489–496. doi: 10.5863/1551-6776-24.6.489.
   PubMedGoogle Scholar
• Xia B, Yang M, Nguyen LH, et al. Regular use of proton pump inhibitor and the risk of inflammatory bowel disease: pooled analysis of 3 prospective cohorts. Gastroenterology. 2021;161(6):1842–1852.e1810. doi: 10.1053/j.gastro.2021.08.005.
   PubMed Web of Science ®Google Scholar
• Abrahami D, Pradhan R, Yin H, et al. Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study. Gut. 2023;72(7):1288–1295. doi: 10.1136/gutjnl-2022-328866.
   PubMed Web of Science ®Google Scholar
• Juillerat P, Schneeweiss S, Cook EF, et al. Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36(3):239–247. doi: 10.1111/j.1365-2036.2012.05173.x.
   PubMed Web of Science ®Google Scholar
• Lu TX, Dapas M, Lin E, et al. The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies. Gut. 2021;70(11):2076–2084. doi: 10.1136/gutjnl-2020-321609.
   PubMed Web of Science ®Google Scholar
• (NorPD) NPD. http://www.reseptregisteret.no/Prevalens.aspx. Vol. 2022.
   Google Scholar
• Kelly OB, Dillane C, Patchett SE, et al. The inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective Cross-Sectional study. Dig Dis Sci. 2015;60(8):2280–2286. doi: 10.1007/s10620-015-3642-8.
   PubMed Web of Science ®Google Scholar
• Koggel LM, Lantinga MA, Büchner FL, et al. Predictors for inappropriate proton pump inhibitor use: observational study in primary care. Br J Gen Pract. 2022;72(725):e899–e906. doi: 10.3399/BJGP.2022.0178.
   PubMed Web of Science ®Google Scholar
• Shah R, Richardson P, Yu H, et al. Gastric acid suppression is associated with an increased risk of adverse outcomes in inflammatory bowel disease. Digestion. 2017;95(3):188–193. doi: 10.1159/000455008.
   PubMed Web of Science ®Google Scholar
• Giannella RA, Broitman SA, Zamcheck N. Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro. Gut. 1972;13(4):251–256. doi: 10.1136/gut.13.4.251.
   PubMed Web of Science ®Google Scholar
• Wilder-Smith CH, Spirig C, Krech T, et al. Bactericidal factors in gastric juice. Eur J Gastroenterol Hepatol. 1992;4:885–891.
   Web of Science ®Google Scholar
• Hassing RJ, Verbon A, de Visser H, et al. Proton pump inhibitors and gastroenteritis. Eur J Epidemiol. 2016;31(10):1057–1063. doi: 10.1007/s10654-016-0136-8.
   PubMed Web of Science ®Google Scholar
• Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–490. doi: 10.1016/j.cgh.2012.12.011.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157(3):682–691.e2. doi: 10.1053/j.gastro.2019.05.056.
   PubMed Web of Science ®Google Scholar
• Shi YC, Cai ST, Tian YP, et al. Effects of proton pump inhibitors on the gastrointestinal microbiota in gastroesophageal reflux disease. Genomics Proteomics Bioinf. 2019;17(1):52–63. doi: 10.1016/j.gpb.2018.12.004.
   PubMed Web of Science ®Google Scholar
• Gubatan J, Boye TL, Temby M, et al. Gut microbiome in inflammatory bowel disease: role in pathogenesis, dietary modulation, and Colitis-Associated Colon cancer. Microorganisms. 2022;10(7):1371. doi: 10.3390/microorganisms10071371.
   PubMed Web of Science ®Google Scholar
• Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13(9):R79. doi: 10.1186/gb-2012-13-9-r79.
   PubMed Web of Science ®Google Scholar
• Takagi T, Naito Y, Inoue R, et al. The influence of long-term use of proton pump inhibitors on the gut microbiota: an age-sex-matched case-control study. J Clin Biochem Nutr. 2018;62(1):100–105. doi: 10.3164/jcbn.17-78.
   PubMed Web of Science ®Google Scholar
• Quévrain E, Maubert MA, Michon C, et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in crohn’s disease. Gut. 2016;65(3):415–425. doi: 10.1136/gutjnl-2014-307649.
   PubMed Web of Science ®Google Scholar
• Zhao H, Xu H, Chen S, et al. Systematic review and meta-analysis of the role of Faecalibacterium prausnitzii alteration in inflammatory bowel disease. J Gastroenterol Hepatol. 2021;36(2):320–328. doi: 10.1111/jgh.15222.
   PubMedGoogle Scholar
• Cohen LJ, Cho JH, Gevers D, et al. Genetic factors and the intestinal microbiome guide development of microbe-based therapies for inflammatory bowel diseases. Gastroenterology. 2019;156(8):2174–2189. doi: 10.1053/j.gastro.2019.03.017.
   PubMed Web of Science ®Google Scholar
• Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307–317. doi: 10.1038/nature10209.
   PubMed Web of Science ®Google Scholar
• Kump P, Wurm P, Grochenig HP, et al. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther. 2018;47(1):67–77. doi: 10.1111/apt.14387.
   PubMed Web of Science ®Google Scholar
• Uygun A, Ozturk K, Demirci H, et al. Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis. Medicine (Baltimore). 2017;96(16):e6479. doi: 10.1097/MD.0000000000006479.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218–1228. doi: 10.1016/S0140-6736(17)30182-4.
   PubMed Web of Science ®Google Scholar
• Cohen-Mekelburg S, Van T, Wallace B, et al. The association Between nonsteroidal anti-inflammatory drug use and inflammatory bowel disease exacerbations: a true association or residual bias? Am J Gastroenterol. 2022;117(11):1851–1857. doi: 10.14309/ajg.0000000000001932.
   PubMed Web of Science ®Google Scholar
• Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141(4):1314–1322.e5. doi: 10.1053/j.gastro.2011.06.075.
   PubMed Web of Science ®Google Scholar
• Marlicz W, Loniewski I, Grimes DS, et al. Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine. Mayo Clin Proc. 2014;89(12):1699–1709. doi: 10.1016/j.mayocp.2014.07.015.
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Toussaint NC, Chen SP, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883–885.e889. doi: 10.1053/j.gastro.2015.06.043.
   PubMed Web of Science ®Google Scholar
• Martinsen TC, Fossmark R, Waldum HL. The phylogeny and biological function of gastric juice-microbiological consequences of removing gastric acid. Int J Mol Sci. 2019;20(23):6031.
   PubMed Web of Science ®Google Scholar
• Levine A, Wine E, Assa A, et al. Crohn’s disease exclusion diet Plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 2019;157(2):440–450.e448. doi: 10.1053/j.gastro.2019.04.021.
   PubMed Web of Science ®Google Scholar
• Olaisen M, Spigset O, Flatberg A, et al. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther. 2019;49(10):1301–1313. doi: 10.1111/apt.15227.
   PubMed Web of Science ®Google Scholar
• Biedermann L, Brulisauer K, Zeitz J, et al. Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH. Inflamm Bowel Dis. 2014;20(9):1496–1501. doi: 10.1097/MIB.0000000000000129.
   PubMed Web of Science ®Google Scholar